Health economic evaluation of ferucarbotran-enhanced MRI in the diagnosis of liver metastases in colorectal cancer patients

Annemans, Lieven; Lencioni, Riccardo; Warie, H; Bartolozzi, Carlo; Ciceri, M.; Müller, U

doi:10.1007/s00384-007-0350-7

Cited by 10 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Relatively few comparable studies on health-economic aspects of contrast agents in liver disease seem to have been published [4,[23][24][25][26]. These have shown that contrastenhanced MRI has the potential to improve medical management and save health-care costs compared with contrast-enhanced CT, mainly due to the avoidance of unnecessary surgical procedures.…”

Section: Confirmed Surgical Plan Modified Surgical Plan No Resectionmentioning

confidence: 98%

“…The findings from the study indicated that Teslascan® MRI was more sensitive than contrast-enhanced CT in the preoperative prediction of the resectability of hepatic lesions, which leads to cost savings, as many cases of unnecessary surgery could be avoided. In a recent study by Annemans et al [4], the healtheconomic impact of ferucarbotran-enhanced MRI in the diagnosis of hepatic colorectal cancer metastases was investigated. A decision-tree comparing diagnosis based on contrast-enhanced spiral CT with ferucarbotran-enhanced MRI was constructed.…”

Section: Confirmed Surgical Plan Modified Surgical Plan No Resectionmentioning

confidence: 99%

“…Since surgical resection of colorectal liver metastases (CLM) is the only potentially curative treatment, an important goal of the diagnostic work-up is to identify those patients who would benefit from surgery [2]. More accurate imaging may also have economic consequences, as pre-operative planning is improved and unnecessary surgery can be avoided [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden

et al. 2009

View full text Add to dashboard Cite

The purpose of this study was to perform an economic evaluation of hepatocyte-specific Gd-EOB-DTPA enhanced MRI (PV-MRI) compared to extracellular contrast-media-enhanced MRI (ECCM-MRI) and three-phase-MDCT as initial modalities in the work-up of patients with metachronous colorectal liver metastases. The economic evaluation was performed with a decision-tree model designed to estimate all aggregated costs depending on the initial investigation. Probabilities on the need for further imaging to come to a treatment decision were collected through interviews with 13 pairs of each a radiologist and a liver surgeon in Germany, Italy and Sweden. The rate of further imaging needed was 8.6% after initial PV-MRI, 18.5% after ECCM-MRI and 23.5% after MDCT. Considering the cost of all diagnostic work-up, intra-operative treatment changes and unnecessary surgery, a strategy starting with PV-MRI with 959 Euro was cost-saving compared to ECCM-MRI (1,123 Euro) and MDCT (1,044 Euro) in Sweden. In Italy and Germany, PV-MRI was cost-saving compared to ECCM-MRI and had total costs similar to MDCT. In conclusion, our results indicate that PV-MRI can lead to cost savings by improving pre-operative planning and decreasing intra-operative changes. The higher cost of imaging with PV-MRI is offset in such a scenario by lower costs for additional imaging and less intra-operative changes.

show abstract

Section: Confirmed Surgical Plan Modified Surgical Plan No Resectionmentioning

confidence: 98%

Section: Confirmed Surgical Plan Modified Surgical Plan No Resectionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In the setting of hepatic imaging, MRI is still widely regarded as a problem‐solving modality in case of equivocal findings on CT or ultrasound imaging, rather than a first‐line imaging modality. However, depending on the number of unclear cases, this might result in an overall increased number of imaging procedures for patients as well as suboptimal use of resources.…”

Section: Introductionmentioning

confidence: 99%

Randomized multicentre trial of gadoxetic acid-enhanced MRIversusconventional MRI or CT in the staging of colorectal cancer liver metastases

Zech

Korpraphong

Huppertz

et al. 2014

British Journal of Surgery

123

View full text Add to dashboard Cite

BackgroundThis multicentre international randomized trial compared the impact of gadoxetic acid-enhanced magnetic resonance imaging (MRI), MRI with extracellular contrast medium (ECCM-MRI) and contrast-enhanced computed tomography (CE-CT) as a first-line imaging method in patients with suspected colorectal cancer liver metastases (CRCLM).MethodsBetween October 2008 and September 2010, patients with suspected CRCLM were randomized to one of the three imaging modalities. The primary endpoint was the proportion of patients for whom further imaging after initial imaging was required for a confident diagnosis. Secondary variables included confidence in the therapeutic decision, intraoperative deviations from the initial imaging-based surgical plan as a result of additional operative findings, and diagnostic efficacy of the imaging modalities versus intraoperative and pathological extent of the disease.ResultsA total of 360 patients were enrolled. Efficacy was analysed in 342 patients (118, 112 and 112 with gadoxetic acid-enhanced MRI, ECCM-MRI and CE-CT respectively as the initial imaging procedure). Further imaging was required in 0 of 118, 19 (17·0 per cent) of 112 and 44 (39·3 per cent) of 112 patients respectively (P < 0·001). Diagnostic confidence was high or very high in 98·3 per cent of patients for gadoxetic acid-enhanced MRI, 85·7 per cent for ECCM-MRI and 65·2 per cent for CE-CT. Surgical plans were changed during surgery in 28, 32 and 47 per cent of patients in the respective groups.ConclusionThe diagnostic performance of gadoxetic acid-enhanced MRI was better than that of CE-CT and ECCM-MRI as the initial imaging modality. No further imaging was needed in the gadoxetic acid-enhanced MRI group and comparison of diagnostic efficacy parameters demonstrated the diagnostic superiority of gadoxetic acid-enhanced MRI. Registration number: NCT00764621(http://clinicaltrials.gov); EudraCT number: 2008-000583-16 (https://eudract.ema.europa.eu/).

show abstract

“…As SPION are magnetic, they can also be used as a contrast agent in MRI for disease diagnosis and treatment monitoring. In fact, several SPION formulations have been approved for clinical use including dextran-coated iron oxide (Feridex ® ) for liver and spleen imaging, and ferumoxytol for iron replacement therapy [83, 84]. SPIONs are safe and stable nanodelivery system to carry genes, including small interfering RNA (SiRNA), nucleic acids and plasmid DNA [85–87], as well as chemotherapy and proteins [88–90].…”

Section: Nanomedicine In Therapeuticsmentioning

confidence: 99%

Nanomedicine: a primer for surgeons

Wong

Liu

2012

Pediatr Surg Int

View full text Add to dashboard Cite

The advances in science have resulted in the emergence of nanotechnology, which deals with the design and use of tools and devices of size 1-100 nm. The application of nanotechnologies to medicine is thus termed nanomedicine. Significant research has been focused on this new and exciting field and this review article will describe the basics of nanomedicine. This is followed by its experimental and clinical applications in diagnostics, drug therapy and regenerative medicine. Safety issues of in vivo use of nanomaterials are also discussed. In the future, it is foreseen that nanomedicine will facilitate the development of personalized medicine and will have a major impact on the delivery of better healthcare.

show abstract

Health economic evaluation of ferucarbotran-enhanced MRI in the diagnosis of liver metastases in colorectal cancer patients

Abstract: In this comparative medical decision analysis, it was shown that ferucarbotran-enhanced MRI has the potential to improve medical management and save health care costs.

Cited by 10 publications

References 11 publications

Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden

Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden

Randomized multicentre trial of gadoxetic acid-enhanced MRIversusconventional MRI or CT in the staging of colorectal cancer liver metastases

Nanomedicine: a primer for surgeons

Contact Info

Product

Resources

About